Journal of Clinical Medicine
Ezetimibe Versus Alirocumab and Plaque Vulnerability in Patients with Acute Coronary Syndrome Not Achieving LDL-Cholesterol Target with Statin Therapy: The COMBI-LLT-ACS Randomized Trial
Par A. N. Kovalskaya, Г. Р. Бикбаева, Dmitry Viktorovich Duplyakov et 3 autres.
Contenu en anglais
Résumé
Objective
To compare two lipid-lowering therapy strategies involving Ezetimibe and Alirocumab on the vulnerability of atherosclerotic plaque (AP) in patients with acute coronary syndrome (ACS) not achieving the LDL-cholesterol target while on intensive statin therapy.